Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Revelation Biosciences, Inc. (REVB : NSDQ)

• Company Description    Revelation Biosciences Inc. is a clinical-stage life sciences company. It focused on the development of immunologic-based therapies for the prevention and treatment of disease. The company's product pipeline includes REVTx-99, REVTx-200 and REVDx-501. Revelation Biosciences Inc., formerly known as Petra Acquisition Inc., is based in NEW YORK. Number of Employees: 9

• Price / Volume Information    Yesterday's Closing Price: $0.76 Daily Weekly Monthly 20 Day Moving Average: 436,833 shares Shares Outstanding: 4.60 (millions) Market Capitalization: $3.50 (millions) Beta: -0.08 52 Week High: $34.24 52 Week Low: $0.70 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.75% -11.80% 12 Week -74.75% -78.82% Year To Date -89.70% -90.35%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4660 LAJOLLA VILLAGE DRIVE SUITE 100 - SAN DIEGO,CA 92122 USA ph: 650-800-3717 fax: - mike@plrinvest.com http://www.revbiosciences.com

• General Corporate Information    Officers James Rolke - Chief Executive Officer and President George Tidmarsh - Chairman Chester S. Zygmont - Chief Financial Officer Jess Roper - Director Jennifer Carver - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 76135L606 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/08/25 Share - Related Items Shares Outstanding: 4.60 Most Recent Split Date: 1.00 (0.06:1) Beta: -0.08 Market Capitalization: $3.50 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.24 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.43 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.24 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 94.64% vs. Previous Quarter: 57.63% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -299.46 12/31/24 - -203.77 ROA 06/30/25 - - 03/31/25 - -115.36 12/31/24 - -90.91 Current Ratio 06/30/25 - - 03/31/25 - 3.60 12/31/24 - 3.43 Quick Ratio 06/30/25 - - 03/31/25 - 3.60 12/31/24 - 3.43 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 3.18 12/31/24 - 9.02 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©